8-K

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

                                   May 2, 2005
- --------------------------------------------------------------------------------
                Date of Report (Date of earliest event reported)


                                 ORAGENICS, INC.
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)


           Florida                    000-50614                  59-3410522
- --------------------------------------------------------------------------------
(State or other jurisdiction         (Commission                (IRS Employer
      of incorporation)              File Number)            Identification No.)

                            13200 Progress Boulevard
                             Alachua, Florida 32615
- --------------------------------------------------------------------------------
           (Address of principal executive offices including zip code)


                                 (386) 418-4018
- --------------------------------------------------------------------------------
               Registrant's telephone number, including area code


                                      None
- --------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)


================================================================================




ITEM 8.01 OTHER EVENTS

      Oragenics, Inc. issued a press release to announce the start of a Phase I
clinical study of its Replacement Therapy technology, a novel approach to the
prevention of tooth decay.


ITEM 9.01 FINANCIAL INFORMATION AND EXHIBITS


     Exhibit No.          Description
     -------------------- -----------------------------------------------------
     99.1                 Press Release
     -------------------- -----------------------------------------------------




                                   SIGNATURES

         In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized on this 2nd day of May, 2005.

                                 ORAGENICS, INC.
                                 (Registrant)


                                 BY: /s/ Mento A. Soponis
                                     -----------------------------------------
                                     Mento A. Soponis
                                     President and Chief Executive Officer

EX-99

                                     [LOGO]


Contact:                                                              For Media:

Chuck Soponis                                                      Joan Kureczka
Chief Executive Officer                               Kureczka/Martin Associates
Oragenics, Inc.                                                   (415) 821-2413
(386) 418-4018                                             Jkureczka@comcast.net

FOR IMMEDIATE RELEASE

   ORAGENICS INITIATES PHASE I SAFETY STUDY OF NOVEL TREATMENT FOR PREVENTING
                                  TOOTH DECAY

ALACHUA, FL (May 2, 2005): Oragenics, Inc. (AMEX:ONI) today announced the start
of a Phase I clinical study of its Replacement Therapy, a novel approach to the
prevention of tooth decay. The study, being conducted in six couples and an
additional nine individuals at Hill Top Research in West Palm Beach, Florida,
will look at the safety of Replacement Therapy and the potential for horizontal
transmission of the Replacement Therapy organism to the non-treated member of
each couple.

"We are very pleased to begin human testing of Replacement Therapy, which our
research to date suggests has great potential as a new preventive therapy
against tooth decay," said Chuck Soponis, Oragenics' president and chief
executive officer.

Tooth decay is caused by lactic acid produced by a naturally occurring bacterium
residing on the tooth surface called Streptococcus mutans. Oragenics'
Replacement Therapy employs a patented strain of S. mutans that is unable to
produce this decay-causing acid. When applied topically to a person's teeth by a
dentist, this engineered bacterium is expected to displace the resident
decay-causing organism, potentially providing life-long protection against most
dental decay.

For this safety study, all of the participants in the trial must be in good
health, without teeth, with full sets of dentures, and under the age of 55.

About Oragenics

Oragenics, Inc. is an emerging biotechnology company focused on the development
and licensure of innovative products and technologies for improving human
health. The company's lead product is a novel oral rinse for the prevention of
tooth decay. The company is also developing a novel antibiotic with
broad-spectrum activity against gram-positive bacteria and a probiotic product
aimed at maintaining oral health. The company is headquartered in Alachua,
Florida. For more information about Oragenics, please consult the company's
website at www.oragenics.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of
1995: This release includes forward-looking statements which reflect Oragenics'
current views with respect to future events and financial performance. These
forward-looking statements are based on management's beliefs and assumptions and
information currently available. The words "believe", "expect", "anticipate",
"intend", "estimate", "project" and similar expressions that do not relate
solely to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they are
subject to a variety of risks, uncertainties, and other factors that could cause
actual results to differ materially from those expressed in any such
forward-looking statements. These factors include, but are not limited to (1)
the ability to successfully complete development and commercialization of
Oragenics' Replacement Therapy for prevention of tooth decay, novel antibiotic,
and probiotic product for oral health; (2) the ability to obtain substantial
additional funding; (3) the ability to develop and commercialize products before
competitors;(4) the ability to develop commercial products with the in-licensed
technology; and (5) other factors detailed from time to time in filings with the
Securities and Exchange Commission. We expressly disclaim any responsibility to
update forward-looking statements.

                                      # # #